Abstract:Objective: To investigate whether there’s any help r elieving the pain of osteoporosis as Zoledronic acid (ZOL) improving bone mineral density(BMD). To observe the effect of ZOL accompanied by calcium and vitamin D on the balance ability in the course of treatment of postmenopausal osteoporosis. Methods: In this self-control, prospective trial, 220 postmenopausal women with osteoporosis(mean age 67 years) were to receive a single infusion of ZOL 5 mg at baseline and month 12. BMD, numerical rating scale(NRS) pain scores and fall index(FI) were measured at baseline, month 12 and 24 (before each use of zoledronic acid). The main outcome measures were the changes in lumbar spine and hip BMD, the changes in NRS pain scores and fall index . The ANOVA and least significant difference ( LSD ) multiple comparison was used for statistical comparison. Results: The patients with postmenopausal osteoporosis had significantly decreased NRS pain scores(P<0.05) with significantly higher lumbar and hip BMD over 2 year treatment of once-yearly ZOL 5 mg. And FI was decreased(P<0.05) with the oral daily elemental calcium and vitamin D in the treatment course. Conclusion: Zoledronic acid relieves pain with increased BMD over 2 years of treatment in women with postmenopausal osteoporosis. ZOL can help improve the balance ability.

The effect of Zoledronic acid on pain and balance in women with postmenopausal osteoporosis